PE
CSTL icon

Point72 Europe’s Castle Biosciences CSTL Stock Holding History

Point72 Europe’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$2.56K Buy
+112
New +$2.27K ﹤0.01% 649

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Europe's CSTL Position: Q3 2025 in Review

Point72 Europe opened a new position in Castle Biosciences (CSTL) in Q3 2025: 112 shares worth $2.56K. The stake represents ﹤0.01% of the portfolio and ranks #649 among its holdings.

173 funds tracked by Wall St. Rank hold CSTL as of Q3 2025.

  • Point72 Europe held 112 shares of Castle Biosciences worth $2.56K as of Q3 2025.
  • Castle Biosciences was a new Point72 Europe position in Q3 2025.
  • Castle Biosciences made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #649 holding.
  • 173 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.